Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s AMGN Prolia ...

Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...

Amgen faces biosimilar or generic competition for several products, which collectively represent less than 5% of total revenues. Patents for RANKL antibodies, affecting Prolia and XGEVA ...

Researchers predicted the likelihood of achieving target T-scores in postmenopausal women with osteoporosis who received denosumab therapy for 10 years.